ANDA 90874, held by Mylan Institutional. Isosulfan Blue.
As of Nov 21, 2026, ANDA 90874 (Isosulfan Blue), held by Mylan Institutional, was first approved by FDA on Jul 20, 2010, with 1 approved supplement and 0 published complete response letters.
Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities. 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2010 | Original application | Approved |
| Isosulfan Blue50MG/5ML (10MG/ML) · solution;subcutaneous | Isosulfan Blue | Rx |
| Isosulfan Blue10MG/ML (10MG/ML) · solution;subcutaneous | Isosulfan Blue | Rx |
| Isosulfan Blue30MG/3ML (10MG/ML) · solution;subcutaneous | Isosulfan Blue | Rx |
| Jan 28, 2026 | Supplement 8Manufacturing | Approved | None posted |
| Jul 20, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters